SCHEMBL3550858

SCHEMBL3550858

OC(=S)c1ccc(OCc2ccccc2)c(C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.57
RXRB P28702 4/20 0.57
RXRG P48443 4/20 0.57
MRGPRX4 Q96LA9 7/20 0.53
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
S1PR1 P21453 1/20 0.43
CTSS P25774 1/20 0.43
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
HTR2C P28335 1/20 0.41
SLC6A4 P31645 1/20 0.41
HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL79709 0.86 RXRA (0.72) RXRARXRBRXRGMRGPRX4
SCHEMBL1437991 0.83 RXRA (0.61) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL10323581 0.83 RXRA (0.61) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL3550855 0.83 RXRA (0.61) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL79430 0.82 RXRA (0.63) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL2950475 0.81 RXRA (0.59) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL3901919 0.81 MRGPRX4 (0.69) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL1437962 0.81 RXRA (0.59) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL22288671 0.80 RXRA (0.51) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL20756090 0.80 RXRA (0.54) RXRARXRBRXRGMRGPRX4CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE RXRA 4524/4885RXRB 4684/4885RXRG 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.